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Abstract
Background: A germ line single nucleotide polymorphism (SNP) in the first intron of the gene encoding
MDM2 at position 309, an important modulator of p53, has been described. BRCA1/2 mutation have been
associated with increased rates of breast cancers with mutated P53. It was shown that the presence of
MDM2 309 SNP correlated with younger cancer onset age in individuals with a p53 mutations. The
differential effects of this SNP were also linked to estrogen receptor activation. Here we report on our
study of 453 Ashkenazi breast cancer patients of whom 180 were positive for the known Ashkenazi
BRCA1/2 mutations
Methods: DNA from breast cancer patients was obtained for analysis of one of the three common
BRCA1/2 mutations and MDM2 SNP309. Data regarding cancer onset and death ages was obtained from
our database and Statistical analysis was performed using the SPSS® statistical package (SPCC Inc., Chicago,
IL), and JMP® software (SAS Institute, Cary, NC).
Results: The percentage of MDM2 SNP309 in control and BRCA 1/2 population which is similar to that
reported for other Jewish Ashkenazi populations at 52.2% for the heterozygotes and 25.0% for
MDM2SNP309G/G and 22.8% for MDM2SNP309T/T.
There was not a statistical significant difference in median age of disease onset in the different MDM2
SNP309 subgroups of the BRCA1/2 carriers. When we further divided the group into under and above 51
years old ( presumed menopause age) in the BRCA1 positive subset we found that there were less patients
of the MDM2SNP309 G/G versus the MDM2SNP309 T/T in the over 51 patient group (p = 0.049). This
result has been obtained in a relatively small subgroup and is of borderline statistical significance.
Interestingly, in the BRCA1/2 mutation carriers, we found a survival advantage for patients harboring the
SNP309 G/G genotype (p = 0.0086) but not for the 272 patients not harbouring this mutations.
Conclusion: MDM2SNP309G/G main effect on BRCA1/2 positive mutation carriers is linked to its effect
on patients survival. Further research is needed in order to understand the reason for this difference.
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MDM2 regulates p53 by targeting its destruction through
the ubiquitin pathway and also by directly blocking p53
transcriptional activity[1]. A single nucleotide polymor-
phism (SNP) in the MDM2 promoter (SNP309) was iden-
tified [2]. Homozygotic SNP309 G/G carriers express
higher levels of MDM2, which can subsequently attenuate
the p53 pathway [2]. A significantly reduced age of onset
for several p53 dependent cancers have been described in
SNP309 G/G homozygous carriers including patients with
Li-Fraumeni syndrome [2]. In contrast, studies have also
shown that SNP309 G/G alone does not have an effect on
the risk or the onset of various cancers, including familial
breast cancer in which mutations for BRCA1 or BRCA2
have not been detected [3].
Two recent articles have studied this subject again with
somewhat conflicting results. Yarden et al [4], studied
BRCA1/2 mutation carriers. They divided this population
into two – those under 51 years old (probably premeno-
pausal), and those over 51 years old. In the under 51 years
old they found a much larger fraction of patients harbor-
ing MDM2 SNP309G/G compared to the fraction of
patients harbouring this SNP in the over 51 years old, sup-
porting a role for this SNP as a modifier of cancer risk in
BRCA1/2 mutation carriers. Wasielewski et al [5],
described a younger cancer onset age for MDM2 SNP309
G/G carriers in a large heterogenous group of patients
with familial breast cancer. However the MDM2 SNP309
G/G correlation with cancer onset age in their study
seemed to be restricted to non mutant breast familial can-
cer cases and was not apparent in the BRCA1/2 mutation
carriers. Bond, Levine and colleagues studied the effects of
SNP309 G/G on breast cancer onset age in a group of
Ashkenazi breast cancer patients who were not BRCA1/2
carriers of mutations. They noted a significantly earlier
cancer onset in women with both a strongly positive estro-
gen receptor expression pattern and the G/G polymor-
phism at the MDM2 309 position [6]. Interestingly, in the
subset without a strongly positive estrogen receptor
expression pattern, there was a trend for disease onset at
an older age in the SNP309 G/G carriers compared to the
SNP309 T/T carriers(p = 0.1). Thus different results as to
the effect of MDM2 309 SNP on breast cancer onset age in
BRCA1/2 mutation carriers and in the non carrier control
Ashkenazi group were obtained by different groups.
Several studies have found negative correlations between
MDM2 tumor expression and prognosis in various can-
cers including breast, ovarian and brain [7-9]. Two studies
have also noted a negative effect of MDM2 SNP309 G/G
on survival of patients with metastatic gastric and renal
cell cancer[10,11]. However in breast cancer a more com-
plex picture emerges from a study by Mathoulin-Portie et
al[12]. This group stained breast cancer tumor samples for
p53, MDM2 and p21 (a p53 regulated gene)and analyzed
survival of those patients following adjuvant anthracy-
clines containing treatments. In their study, the p53+/
p21+/MDM2+ tumors were associated with a better out-
come than the p53+/p21+/MDM2- tumors. These results
imply that the relationship between MDM2 expression
and survival is not simple and may depend on specific
tumor characteristics and clinical circumstances.
Estrogen seems also to influence the magnitude of the
MDM2 SNP309 G/G effects on MDM2 expression. Estro-
gen receptor which has a DNA binding site close to the
Sp1 site which is directly influences by MDM2 SNP309 G/
G. Bond, Levine and colleagues have described a signifi-
cant correlation between MDM2 SNP309 G/G and the
prevalence of diffuse large cell lymphoma and soft tissue
sarcoma, in women under the age of 51 (persumably pre-
menopausal) [6]. This findings support a role for estrogen
in the MDM2 SNP309 G/G effects on carcinogenesis.
We have obtained DNA samples from a large group of
breast cancer patients (nearly all Jewish Ashkenazi) for
analysis of BRCA1/2 mutations and modifier genes. Here
we describe the interactions we found out in this group
between MDM2 SNP309 G/G, BRCA1/2 mutations and
clinical findings including cancer onset age, survival, and
the presence of other cancers.
Methods
Study population
DNA was from breast cancer patients obtained for analysis
of their BRCA status and modifier genes (see Table 1 for
specific mutations). These patient population does not
contain all breast cancer patients presenting to our clinic
but all of those who agreed for genetic testing. Thus this
patient population presumably contains a relatively high
percentage of breast cancer patients who had reasons to
agree for genetic testings such as other cases of cancer in
the family, younger cancer onset age etc. All participants
signed an informed consent approved by the institutional
ethics committee. In the Jewish Ashkenazi population
there is an especially high prevalence of BRCA1/2 [13,14],
which constitute a high percentage of our patient popula-
tion. All of the patients had been diagnosed with breast
cancer and analyzed for one of the common three
Ashkenazi mutations in the BRCA genes which account
for probably more than 95% of all Ashkenazi patients har-
boring BRCA mutations.
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Genomic DNA was extracted according to standard proto-
cols, and used as a template for the PCR reaction. BRCA
mutations were analyzed by a combiniation of multiplex
PCR with specific primers, and restriction site analysis as
described in detail by Abeilovich and colleagues [15].
MDM2 was analyzed for SNPs using either bidirectional
sequencing of a fragment of DNA amplified from the
MDM2 human promoter (primer 1: CGGGAGTTCAGGG-
TAAAGGT and primer 2: GCAAGTCGGTGCTTACCTG
(2)) or a gel analysis of restriction of the same DNA frag-
ment by Msp A1I (New England Biolabs, Ipswich, MA).
Statistical methods
Follow up was calculated from the time of diagnosis to
date of last follow-up. The rate of death was estimated
using Kaplan-Meier methods. Statistical analysis was per-
formed using the SPSS® statistical package (SPCC Inc.,
Chicago, IL), and JMP® software (SAS Institute, Cary, NC).
Assessment of the correlations between genetic carrier sta-
tus and MDM2 was carried out using the Fisher Exact test
or Chi-Squared test. A p value < 0.05 was considered sig-
nificant. Similar methodology was used to assess the cor-
relation between the frequency of other cancers and
MDM2 SNP309 status
Results
We evaluated DNA samples from 180 Ashkenazi breast
cancer BRCA1/2 positive (Table 1), and from 272 patients
who tested negative for these three Ashkenazi mutations.
There was no significant difference between the preva-
lence of the different MDM2 SNP309 alleles between the
BRCA1/2 patients (Table 2a) and the non carrier group
(Table 2b). Disease onset age of breast cancer did seem to
vary according to MDM2 309SNP genotype in the BRCA1/
2 groups (Fig 1A). Similar to the data presented for
women without high expression of estrogen receptors [6],
there was a trend for disease onset at a higher age in the G/
G MDM2 309 group than in the T/T group in the non-
BRCA mutation carriers (Fig. 1B and Table 3). Our data
did not distinguish between high and low estrogen recep-
tor expressers therefore we could not asses a correlation
between high estrogen receptor expression and disease
onset age in a similar manner to that performed by Bond
and colleagues.
Recently Yarden and colleagues divided the breast cancer
patient group to those with tumors diagnosed under the
age of 51 and those above 51. In a similar patient group
to ours they demonstrated a significantly decreased per-
centage of MDM2 309 G/G patients in the over 51
BRCA1/2 carriers compared to the other genotypes[4].
However when we have done similar analysis we did not
note such a difference. When we limited our comparison
to MDM2 309 G/G versus T/T (without taking into
account the heterozygotes group) we noted in the BRCA1/
2 group a trend for lower frequency of G/G in the over 51
year old group (p = 0.069) and this trend reached statisti-
cal significance in BRCA1 positive group only (Fig 1c and
1d p = 0.049). The number of patients over 51 was limited
and these results which are of borderline statistical signif-
icance must be regarded as "hypothesis generating data"
and be confirmed in a much larger data set. Thus it seems
that at least in our cohort the effects of MDM2309 geno-
type on cancer onset age are very limited.
Our next step was to study the survival of the different sub-
populations according to the three different genotypes (T/
T, G/G or G/T at the -309 position of the MDM2 gene).
There was a distinct survival advantage in the BRCA1/2
mutation carrier group for the patients homozygous for G/
Table 2: Prevalence of MDM2SNP309 subtypes
a: Prevalence of the MDM2 SNP309 subtypes in BRCA mutation carriers
BRCA1 BRCA2 BRCA1+2 Total
Homozygotes G-G 29(26.1)% 16(23%) 45(25%)
Hetrozygotes 55(49.5%) 39(57.3%) 94(52.2%)
Homozygotes T-T 27(24.3%) 13(19.1%) 1(100%) 41(22.7%)
Total 111 68 1 180
b: Prevalence of the MDM2 SNP309 subtypes in the overall population
BRCA Carriers Non Carriers
Frequency Percent Frequency Percent
Homozygotes G-G 45 25.00% 68 25.00%
Hetrozygotes 94 52.20% 139 51.10%
Homozygotes T-T 41 22.80% 65 23.90%
Total 180 272Page 3 of 7
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Cancer onset age in the BRCA1/2 mutation carriers (A) and BRCA1/2 non carriers (B), according to their MDM2 SNP-309 subtypesFigure 1
Cancer onset age in the BRCA1/2 mutation carriers (A) and BRCA1/2 non carriers (B), according to their 
MDM2 SNP-309 subtypes. C and D prevalence of the SNP MDM309 genotypes in women above and bellow 51 years old – 
C total carrier population and D only BRCA1 mutation carriers.
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BMC Cancer 2009, 9:60 http://www.biomedcentral.com/1471-2407/9/60G at the -309 position, compared to the patients harboring
the SNP309 G/T or T/T (Fig 2a p = 0.0086 log rank test,
median survival 290 versus 412 months). This advantage
was not found in the non BRCA1/2 carriers (Fig. 2b). Cox
multivariate analysis did not reveal modification of the
MDM2 SNP309 effect on survival due to cancer onset age.
Discussion
In the current study we analyzed the relationship between
MDM2 309 SNP status and cancer in a large group of
Ashkenazi patients including a large group of BRCA1/2
mutation carriers Our results revealed high percentage of
MDM2 309 SNP in this population of around a quarter of
all women. This high prevalence of MDM2 309 SNP G/G
in Ashkenazi women has been demonstrated by others
before us. Yarden and colleagues recently presented data
supporting the notion that the relative enrichment in
MDM2 309 SNP G/G in Ashkenazi is a result of a selection
process favoring this single nucleotide polymor-
phism[16]. Currently we don't understand the possible
advantages of this polymorphism which has been linked
to increased incidence of cancer, though recently in the
2008 AACR meeting A Levine presented preliminary evi-
dence supporting a role for the p53 pathway(thus also
MDM2) in regulation of newborn numbers.
We did not detect significant difference in cancer onset age
in BRCA1/2 carriers harboring the different MDM2
SNP309 (Fig 1). These results are similar to those presented
by Eccles and colleagues in a small study of BRCA1 positive
patients [17]. Similarly Wasieleski and colleagues have not
noted a higher frequency of MDM2 309 SNP G/G in
younger BRCA1/2 breast cancer patients[5]. In contrast to
that Yarden et al did find an earlier onset age for patients
under 51 who harbor BRCA 1/2 mutations and MDM2 309
SNP G/G [4]. When we analyzed our data regarding onset
age by dividing the whole patient group into those younger
and older than 51, we found only in the BRCA1/2 carrier
group a decreased percentage of MDM2 309 SNP G/G in
the over 51 patient group (Fig 1c and 1d). However only
when comparing this percentage to that of MDM2 309 SNP
T/T in the BRCA1 carrier group (excluding the BRCA2 carri-
ers) MDM2SNP G/G prevalence among the over 51








P value 0.005 0.2
Breast cancer onset age in the BRCA1/2 carriers and non carrier 
group.
Survival analysis of BRCA1/2 mutation carriers (A) and non carriers (B) according to their MDM2 SNP typeFigure 2
Survival analysis of BRCA1/2 mutation carriers (A) and non carriers (B) according to their MDM2 SNP type. 
SNP309 G/G carriers were compared to the combined group of SNP309 G/T and SNP309 T/T. In the BRCA carrier group 
there were 41 G/G patients of whom 7 died (median survival 412 months) while in the combined SNP309 G/T and T/T group 
there were 126 patients of whom 35 died (median survival 301 months). According to a log-rank test the significance of the dif-
ference in survival was P = 0.0086. In the control group the survival for the MDM2 SNP309 G/G carriers was was not statisti-
cally different (p = 0.8).Page 5 of 7
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the MDM2SNP T/T group (p = 0.049) (see fig 1c and 1d).
Thus it seems while we detected some effect of MDM2SNP
G/G on cancer prevalence in the younger than 51 years old,
this effect was significantly smaller compared to that
described by Yarden and colleagues[4].
The effect of the MDM2 SNP 309 G/G on cancer risk has
been recently reviewed in a meta- analysis by Wilkeming
and colleagues[18]. These authors concluded that "The
data show that SNP309 alone has little or no effect on the
risk of common cancers, but it might modify the time of
tumor onset and prognosis". If one only studies the effects
on median onset age of breast cancer in BRCA 1/2 patients
the effect is small indeed, yet we also studied effects of
MDM2 polymorphysm on survival in this group and here
our results suggests a more profound role for the MDM2
SNP309 polymorphism.
When combining the BRCA1 and BRCA 2 mutation carri-
ers we noted significantly better prognosis for the MDM2
SNP309 G/G carriers than for the other MDM2 SNP309
carriers (p = 0.0086). This are supposedly the tumors with
higher levels of MDM2 expression. Cancers in BRCA1 and
BRCA2 mutation carriers have substantial difference
between them[19]. However in both BRCA1 and BRCA2 a
special link to p53 has been described in animal and
human. Furthermore, both BRCA1 and BRCA2 can form a
complex with distinct cellular roles. A higher percentage
of p53 mutations have been detected in the tumors of
both BRCA1/2 mutation carriers. Thus it seems that simi-
lar mechanisms relating to these tumors and P53 (and
therefore MDM2) might take place.
Since MDM2 is an oncogene it seems counterintuitive that
patients in which higher levels of MDM2 are expected will
have longer survival. A possible explanation for such a coun-
terintuitive result is based on our understanding of the role
of p53 in carcinogensis. The presence MDM2 SNP309 G/G
may lead to the overexpression of MDM2 and therefore
cause downregulation of p53 in an effective manner and
render mutational inactivation of p53 unnecessary. Thus
tumors with MDM2 SNP309 G/G might still harbor a poten-
tially active p53. Indeed, when Allazzouzi and colleagues
studied p53 in colon cancer of SNP309 G/G carriers), they
found a higher tumor prevalence of non dominant p53
mutations[20]. When p53 is downregulated in the tumor
not through mutational inactivation but through overex-
pression of an inhibitor certain treatments may allow reacti-
vation of p53. Reactivating P53 may allow better response to
anticancer agents. It is noteworthy that DNA damaging
agents can significantly lower the levels of active MDM2 thus
allowing the reactivation of p53 [21-23].
Therefore a possible scheme to explain a role for MDM2
SNP309 G/G in BRCA tumors could be that overexpres-
sion of MDM2 in BRCA1/2 tumors results in down-regu-
lation of p53 and allows the development of BRCA1/2
tumors similar to the effect induced by a mutation in p53.
Cells overexpressing MDM2 still contain p53 that in cer-
tain conditions. in which MDM2 is inactivated might be
functional. As described MDM2 is inactivated by DNA
damaging agents which includes chemotherapies. This
hypothesis concurs with the hypothesis suggested by
Mathoulin-Portie in their study of anthracyclin treated
breast cancer women ([12]see introduction). These
authors suggested that the better survival observed for
p53+MDM2 + patients compared for the P53+MDM2-
chemotherapy is a result of a different kind of p53 found
in these tumors.
MDM2 SNP309G/G effects on BRCA1/2 positive tumors
might be similar to that of the oncogene BCL6 on diffuse
large cell lymphomas. Similarly to MDM2, BCL6 can
down-regulate p53 function (though through transcrip-
tional rather than post transcriptional control). This has
been proposed as one of the main mechanisms of onco-
genic transformation induced by this protein[24]. Moreo-
ver similarly to MDM2 it has been recently demonstrated
that genotoxic stress can cause downregulation of
BCL6[25]. Interestingly, BCL6 expression in diffuse large
B cell lymphomas has been shown to strongly correlate
with better survival in patients with this disease[26]. Thus,
both BCL6 and MDM2 may cause down-regulation of
wild type p53 and perhaps allow the emergence of tumors
with non dominant negative p53. Such tumors might ulti-
mately be more sensitive to therapy than tumors with
mutated p53 if the anti-tumor therapy resulted in reacti-
vation of a functional p53. When suggesting this hypoth-
esis its important to note that both BCL6 and MDM2 have
a variety of roles unrelated to p53 that could explain asso-
ciation between their increased expression and improved
prognosis [1].
Recently two articles assessing the relationship between
patients' survival and the MDM2 SNP309 were published.
However, it is important to note that the patients in those
studies suffered from a different disease than those in the
current study and were treated with different therapies than
those commonly used for treatments of breast cancer.
Conclusion
Our data demonstrate that patients with BRCA1/2 breast
cancers harboring any of the three MDM2 SNP309 had
similar cancer onset ages. Only by studying the over 51
years old group of patients (presumably post menopau-
sal) we could detect a difference between the different
MDM2 SNP309 genotypes – only in the BRCA1 mutation
carriers. The relative percentage of the MDM2SNP309G/G
carriers was reduced in this group of patients compared to
the younger than 51 years old (p = 0.049). While this
results concurs with those of Yarden and colleagues theyPage 6 of 7
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need reaffirmation in larger studies.
MDM2 SNP309G/G BRCA1/2 carriers had significantly
longer survival compared to the combination of the other
MDM2 SNP309 subgroups (p = 0.0086). This somewhat
surprising result may be a result of differential sensitivity
to adjuvant therapy in this subgroup. Further studies on
MDM2 SNP309 may provide important insights as to fac-
tors effecting tumorigenesis and drug sensitivity in
BRCA1/2 mutation carriers.
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